Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$142.1 million.

  • Centessa Pharmaceuticals' Free Cash Flow fell 173.29% to -$58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$181.0 million, marking a year-over-year decrease of 38.87%. This contributed to the annual value of -$142.1 million for FY2024, which is 11.48% up from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' Free Cash Flow is -$142.1 million, which was up 11.48% from -$160.5 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Free Cash Flow ranged from a high of -$10.6 million in FY2020 and a low of -$201.7 million during FY2022.
  • Over the past 3 years, Centessa Pharmaceuticals' median Free Cash Flow value was -$160.5 million (recorded in 2023), while the average stood at -$168.1 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Free Cash Flow crashed by 1,172.77% in 2021, and later climbed by 20.41% in 2023.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' Free Cash Flow stood at -$10.6 million in 2020, then tumbled by 1,172.77% to -$135.3 million in 2021, then crashed by 49.07% to -$201.7 million in 2022, then grew by 20.41% to -$160.5 million in 2023, then grew by 11.48% to -$142.1 million in 2024.